Porownywarka

Cartalax vs Epithalon side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

CartalaxEpithalon

Udostępnij porównanie peptydów

Wlasciwosc	Cartalax	Epithalon
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Ala-Glu-Asp, AED Tripeptide	Epitalon, Epithalone, AGAG
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Available in Russia; not FDA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Joint health, cartilage support, osteoarthritis	Longevity, telomere support, anti-aging, sleep
Jak dziala	Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typowe dawkowanie	Limited community data available · See research protocols	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Dawkowanie z badań	10-20 mg daily · 10-30 day courses · Oral	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typowy czas trwania	10-30 day courses	10-20 day cycles
Podanie	Oral	Subcutaneous or intramuscular injection
Timing	Morning or as directed With or without food	Before bed With or without food
Poziom dowodów	Przedkliniczne	Badania kliniczne
Mozliwe skutki uboczne	Generally well-tolerated (Reported by the source, but safety documentation is limited.) Mild injection site reactions (Listed as a mild reported effect.) Transient fatigue (Listed as a reported transient effect.) +2 więcej Mild gastrointestinal upset (Described by the source as rare.) Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 więcej Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Podsumowanie researchu	The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
Referencje	Peptibase peptides Peptibase peptides +1 więcej Peptibase peptides	PubMed PubMed +2 więcej WikipediaEpitalon Springer
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Cartalax

Epithalon

Kategoria

Bioregulatory

Znany tez jako

Ala-Glu-Asp, AED Tripeptide

Epitalon, Epithalone, AGAG

Zatwierdzony przez FDA

Nie

Status kliniczny

Available in Russia; not FDA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Joint health, cartilage support, osteoarthritis

Longevity, telomere support, anti-aging, sleep

Jak dziala

Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typowe dawkowanie

Limited community data available · See research protocols

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Dawkowanie z badań

10-20 mg daily · 10-30 day courses · Oral

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typowy czas trwania

10-30 day courses

10-20 day cycles

Podanie

Oral

Subcutaneous or intramuscular injection

Timing

Morning or as directed

With or without food

Before bed

With or without food

Poziom dowodów

Przedkliniczne

Badania kliniczne

Mozliwe skutki uboczne

Generally well-tolerated (Reported by the source, but safety documentation is limited.)
Mild injection site reactions (Listed as a mild reported effect.)
Transient fatigue (Listed as a reported transient effect.)

+2 więcej

Mild gastrointestinal upset (Described by the source as rare.)
Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 więcej

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Podsumowanie researchu

The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

Referencje

Peptibase peptides Peptibase peptides

+1 więcej

Peptibase peptides

PubMed PubMed

+2 więcej

WikipediaEpitalon Springer

Pełny profil

Zobacz szczegóły